Avalo Therapeutics announced positive Phase 2 results for Abdakibart (AVTX-009) in treating moderate to severe hidradenitis suppurativa (HS). The LOTUS trial met its primary endpoint with response rates over 42% at Week 16, the highest observed in trials of this size, showing significant improvement in key clinical measures. Abdakibart was well tolerated with a favorable safety profile, and Avalo plans to advance the drug into Phase 3 registrational trials. This progress highlights the potential of IL-1β inhibition as a new treatment option for HS patients.
YieldMax ETFs announced weekly distributions for their Group 1 ETFs, with distribution rates ranging from 26.17% to 60.34% annualized. These ETFs cover sectors like semiconductors, AI & tech, crypto, metals, and covered call strategies. Distributions...
The global ultrasonic aspirator market, valued at $194 million in 2025, is projected to grow at a CAGR of 6.87% to reach $376 million by 2035. Growth is fueled by increased use in neurosurgery, orthopedic, and minimally invasive surgeries, driven by ...
MEXC's RealStocks platform, launched in June 2026, saw SpaceX (SPCX) capture nearly 30% of trading volume and user activity, marking it as the most popular stock among over 7,000 US stocks and ETFs available. AI-related stocks collectively accounted ...
The SCHD ETF currently offers a 3.3% yield and is on track to complete its 15th consecutive year of dividend increases in 2026. This consistent dividend growth highlights SCHD's appeal for income-focused investors seeking reliable payouts. Maintainin...
Dimensional Fund Advisors Ltd. has publicly disclosed holding a 1.26% ownership stake in Prologis Inc, totaling 11,789,090 shares as of July 27, 2026. This disclosure is made under Rule 8.3 of the Takeover Code, indicating a significant investment po...
